

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Colorectal cancer	Tankyrase TRF1-interacting ankyrin-related ADP-ribose polymerase (TNKS); TNKS2	<p>Mouse studies suggest small molecule inhibitors of TNKS and TNKS2 could be useful for treating colorectal cancer. In a mouse xenograft model for colorectal cancer, dual inhibitors of TNKS and TNKS2 decreased wingless-type MMTV integration site (WNT) signaling and tumor growth compared with vehicle. Next steps include improving tolerability, optimizing dosage and selecting a preclinical candidate. Novartis AG has discovery-stage TNKS and TNKS2 inhibitors for various cancers.</p> <p><b>SciBX 6(16); doi:10.1038/scibx.2013.385</b>  <b>Published online April 25, 2013</b></p>	Patented; licensing status undisclosed	<p>Lau, T. <i>et al. Cancer Res.</i>; published online March 28, 2013;            doi:10.1158/0008-5472.CAN-12-4562  <b>Contact:</b> Mike Costa, Genentech Research &amp; Early Development, South San Francisco, Calif.            e-mail:  <a href="mailto:mcosta@gene.com">mcosta@gene.com</a></p>